FOLLOWUS
What has been overlooked on study of Chinese materia medica in the West?
- Chinese Journal of Integrative Medicine Vol. 21, Issue 7, Pages: 483-492(2015)
- Affiliations：
Traditional Chinese Medicine Health Education and Research Center, Diamond Bar,CA,USA
- Author bio：
- Funds：
DOI：10.1007/s11655-015-2081-x
CLC：Published：2015，
Published Online：9 July 2015，
Scan for full text
Liu, W.J. What has been overlooked on study of Chinese materia medica in the West?., Chin. J. Integr. Med. 21, 483–492 (2015). https://doi.org/10.1007/s11655-015-2081-x
Willow J.H. Liu. What has been overlooked on study of Chinese materia medica in the West?. [J]. Chinese Journal of Integrative Medicine 21(7):483-492(2015)
Liu, W.J. What has been overlooked on study of Chinese materia medica in the West?., Chin. J. Integr. Med. 21, 483–492 (2015). https://doi.org/10.1007/s11655-015-2081-x DOI：
Willow J.H. Liu. What has been overlooked on study of Chinese materia medica in the West?. [J]. Chinese Journal of Integrative Medicine 21(7):483-492(2015) DOI： 10.1007/s11655-015-2081-x.
摘要
Chinese materia medica (CMM)
including Chinese herbal
animal
and mineral medicine
has been widely researched in the past century for their biological and pharmacological activities. However
their mechanism and clinical efficacy studies did not always give expected results. For example
the most commonly used Chinese herb for menstrual disorders
Radix Angelicae sinensis
showed neither estrogenic nor progesteronic activity in laboratory and clinical studies. Its efficacy should not be denied simply based on such results
because it is mostly used together with other herbs in formulae. Moreover
its regulation on menstruation may take effect through other mechanisms
such as regulation of blood circulation. The key difference of Chinese medicine (CM) from conventional medicine is its unique holistic view on human body and diseases. CMM is mostly applied in clinic in the form of formulae. Study on individual CMM
simply using methods for development of conventional drugs
is unable to thoroughly reveal the power of CMM formulae. The reason may partly result from improper design due to the lack understanding about application principle of CMMs in CM
and/or to current lack of knowledge about the causes of some symptoms and diseases. This paper will introduce the importance of qi and blood in CM etiology and pathology
Zheng differentiation
formulation of CMMs
and explain why one formula can treat different diseases and one disease can be treated with different formulae. Examples in the paper will demonstrate that proper studies on Zheng and its corresponding clinically proven formulae could help scientists find new direction to explain and treat symptoms and diseases that so far modern medicine has been unable to
provided that the designer properly understands CM theories
etiology and pathology of CM
as well as modern medicine. Strategy suggestions about research methods for CMM and its formulae will be given at the end.
Abstract
Chinese materia medica (CMM)
including Chinese herbal
animal
and mineral medicine
has been widely researched in the past century for their biological and pharmacological activities. However
their mechanism and clinical efficacy studies did not always give expected results. For example
the most commonly used Chinese herb for menstrual disorders
Radix Angelicae sinensis
showed neither estrogenic nor progesteronic activity in laboratory and clinical studies. Its efficacy should not be denied simply based on such results
because it is mostly used together with other herbs in formulae. Moreover
its regulation on menstruation may take effect through other mechanisms
such as regulation of blood circulation. The key difference of Chinese medicine (CM) from conventional medicine is its unique holistic view on human body and diseases. CMM is mostly applied in clinic in the form of formulae. Study on individual CMM
simply using methods for development of conventional drugs
is unable to thoroughly reveal the power of CMM formulae. The reason may partly result from improper design due to the lack understanding about application principle of CMMs in CM
and/or to current lack of knowledge about the causes of some symptoms and diseases. This paper will introduce the importance of qi and blood in CM etiology and pathology
Zheng differentiation
formulation of CMMs
and explain why one formula can treat different diseases and one disease can be treated with different formulae. Examples in the paper will demonstrate that proper studies on Zheng and its corresponding clinically proven formulae could help scientists find new direction to explain and treat symptoms and diseases that so far modern medicine has been unable to
provided that the designer properly understands CM theories
etiology and pathology of CM
as well as modern medicine. Strategy suggestions about research methods for CMM and its formulae will be given at the end.
关键词
Chinese Medicineetiology and pathologyZheng differentiationChinese Materia Medicaformulation
Keywords
Chinese Medicineetiology and pathologyZheng differentiationChinese Materia Medicaformulation
references
Tu YY. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011;17:1217᾿220.
Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001;6:S1–S2.
State Administration of Traditional Chinese Medicine. Chinese herbal medicine. Shanghai: Shanghai Science and Technology Publisher;1999.
Liu JL, Burdette JE, Xu HY, Gu C, van Breemen RB, Bhat KP, et al. Evaluation of estrogenic activities of plant extracts on the potential treatment of menopausal. J Agric Food Chem 2001;49:2472᾿479.
Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997;68:981᾿86.
Liu JH. Traditional herbal medicine research methods: identification, analysis, bioassay, and pharmaceutical and clinical studies. Hoboken: John Wiley & Son:2011:8᾿2.
Cheung F. TCM: made in China. Nature 2011:480:S82–S83.
Xu ZG. Modernization: one step at a time. Nature 2011;480:S90–S92.
Tian P. Convergence: where West meets East. Nature 2011;480:S84–S86.
Chen SL, Song JY, Sun C, Xu J, Zhu YJ, Verpoorte R, et al. Herbal genomics: examining the biology of traditional medicine. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing Office 2015:S27–S29.
Guo DA, Wu WY, Ye M, Liu X, Cordell GA. A holistic approach to the quality control of traditional Chinese medicine. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing office. 2015:S29–S34.
Gilbert N. Regulations: herbal medicine rule book. Nature 2011;480:S98–S99.
Jiang J. Patents: protecting China’s national treasure. Nature 2011;480:S93.
Liu L, Leung EL, Tian XY. Perspective: the clinical trial barriers. 2011;480:S100.
Sakurai M. Perspective: herbal dangers. Nature 2011;480:S97.
Williamson EM, Chan K, Xu QH, Nachtergaet A, Bunel V, Zhang, L. et al. Evaluating the safety of herbal medicines: integrated toxicological approaches. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing Office. 2015:S47–S49.
Yang ZF, Leung HEL, Liu L, Jiang ZH, Zhong NS. Developing influenza treatments using traditional Chinese medicine. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing Office. 2015:S35–S37.
Lau GBS, Yue GGK, Fung KP, Tan NH, Leung, PC. The potential role of Chinese herbal medicine in cancer treatment. The art and science of Traditional Medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing office. 2015:S45–S47.
Liu RH, Runyon RS, Wang YH, Oliver SG, Fan TP, Zhang WD. Deciphering ancient combinatorial formulations: the Shexiang Baoxin Pill. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing office. 2015:S40–S42.
Lam W, Liu SH, Jiang Z, Cheng YC. Lessons from the development of the traditional Chinese medicine formula PHY906. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing Office. 2015:S43–S44.
Zhao XF, Zheng XH, Fan TP, Li ZJ, Zhang YY, Zheng JB. A novel drug discovery strategy inspire by traditional medicine philosophies. The art and science of traditional medicine. Part 2: Multidisciplinary approaches for studying traditional medicine. Science/AAAS Custom Publishing Office. 2015:S38–S40.
Cheng XN, ed. Chinese acupuncture and moxibustion (Revised edition). Beijing: Foreign Languages Press;1999:51᾿9, 254᾿61.
Ray O. The revolutionary health science of psychoendoneuroimmunology: a new paradigm for understanding health and treating illness. Ann NY Acad Sci 2004;1032:35᾿1.
Shen YJ, Chen CX, eds. Pharmacology of Chinese material medica. In: Shen YJ, Chen CY, eds. Pharmacology of Chinese material medica. Shanghai: Shanghai Science and Technology Press; 2008:117,186.
Appleton N, ed. Stopping inflammation: relieving the cause of degenerative diseases. Garden City Park: Square One Publishers;2005:57᾿19.
Yan DX, ed. Aging & blood stasis—A new TCM approach to geriatrics. Boulder: Blue Poppy Press;1995:1᾿8.
Chang JB, Prasad K, Olsen ER, eds. Textbook of angiology. New York: Springer Verlag;2000.
Callahan AS, ed. The next medical revolution—angiology. St. Albans: Altman Publishing;2004:1᾿.
Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu AP, et al. Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol 2012;140:634᾿42.
Deng TT, Han ZQ, eds. Diagnosis of traditional Chinese medicine. Shanghai: Shanghai Science and Technology Publishing House; 1983:122.
Zheng HS, Jiang J, Jia W. Review of modern research of Kidney yang deficiency in Chinese medicine. Liaoning J Tradit Chin Med (Chin) 2007;34:1014᾿015.
Wang YH, Xu AL. Zheng: a systems biology approach to diagnosis and treatment. The art and science of traditional medicine. Part 1: TCM today—a case for integration. Science/AAAS Custom Publishing Office. 2015:S13-S15.
Liu JH. Research on Chinese materia medica should be based on clinical practice—Suggestions about study on Chinese herbal formulae. Clin J Chin Med (Chin) 2014;6(27):4᾿.
Liu JH, Zschocke S, Reininger E, Bauer R. Inhibitory effect of Angelica pubescens on 5-lipooxygenase and cyclooxygenase. Planta Med 1998;64:525᾿29.
Liu JH, Burdette JE, Sun Y, Deng S, Schlecht SM, Zeng W, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnuscastus L. (chaste berry). Phytochemistry 2004;11:18᾿3.
Bensky D, Barolet R. Chinese herbal medicine: formula & strategies. Seattle: Eastland Press;1990:4᾿.
Bensky D, Clavey S, Stoger E. Chinese herbal medicine: Materia Medica. 3rd ed. Seattle: Eastland Press; 2004:14᾿5.
Zhao DM. Study on the compatibility of composite herbal medicines of the Wuzhuyu Decoction. World Sci-Tech Res Develop 1999;21:46᾿0.
Shen YJ, Chen CY, eds. Pharmacology of Chinese material medica. Shanghai: Shanghai Science and Technology Press;2008:187᾿91.
Kang SB, Yuan J eds., ZHANG Zhong-jing medical formula essentials. Shijiazhuang: Hebei Science and Technology Press;2004.
Sakamoto S, Yoshino H, Shirahata Y, Shimodairo K, Okamoto R. Pharmacotherapeutic effects of Kuei-chih-fuling-wan (Keishi-bukuryo-gan) on human uterine myomas. Am J Chin Med 1992;20,313᾿17.
Mori T, Sakamoto S, Singtripop T, Park MK, Kato T, Kawashima S, et al. Suppression of spontaneous development of uterine adenomyosis by a Chinese herbal medicine, keishibukuryo-gan, in mice. Planta Med 1993;59:308᾿11.
Chen JT, Shiraki M. Menopausal hot flash and calciotonin gene-related peptide; effect of Keishi-bukuryo-gan, a kampo medicine, related to plasma calciotonin gene-related peptide level. Maturitas 2003;45:199᾿04.
Noguchi M, Ikarashi Y, Yuzurihara M. Effects of the Japanese herbal medicine Keishi-bukuryo-gan and 17betaestradiol on calcitonin gene-related peptide-induced elevation of skin temperature in ovariectomized rats. J Endocrinol 2003;176:359᾿66.
Sakamoto S, Kudo H, Kawasaki T, Kuwa K, Kasahara N, Sassa S, et al. Effects of a Chinese herbal medicine, Keishi-bukuryo-gan, on the gonadal system of rats. J Ethnopharmacol 1988;23:151᾿58.
Hikiami H, Goto H, Sekiya N, Hattori N, Sakakibara I, Shimada Y, et al. Comparative efficacy of Keishi-bukuryogan and pentoxifylline on RBC deformability in patients with "oketsu" syndrome. Phytomedicine 2003;10:459᾿66.
Goto H, Shimada Y, Sekiya N, Yang Q, Kogure T, Mantani N, et al. Effects of Keishi-bukuryo-gan on vascular function and hemorheological factors in spontaneously diabetic (WBN/kob) rats. Phytomedicine 2004;11:188᾿95.
Nakagawa T, Yokozawa T, Terasawa K, Nakanishi K. Therapeutic usefulness of Keishi-bukuryo-gan for diabetic nephropathy. J Pharm Pharmacol 2003;55:219᾿27.
Sekiya N, Tanaka N, Itoh T, Shimada Y, Goto H, Terasawa K. Keishi-bukuryo-gan prevents the progression of atherosclerosis in cholesterol-fed rabbit. Phytother Res 1999;13:192᾿96.
Sekiya N, Goto H, Tazawa K, Oida S, Shimada Y, Terasawa K. Keishi-bukuryo-gan preserves the endothelium dependent relaxation of thoracic aorta in cholesterol-fed rabbit by limiting superoxide generation. Phytother Res 2002;16:524᾿28.
Fujimoto M, Tsuneyama K, Kinoshita H, Goto H, Takano Y, Selmi C, et al. The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. Ann N Y Acad Sci (2010);1190:151᾿58.
Nagata Y, Goto H, Hikiami H, Nogami N, Fujimoto M, Shibahara N, et al. Effect of Keishibukuryogan on endothelial function in patients with at least one component of the diagnostic criteria for metabolic syndrome: a controlled clinical trial with crossover design. Evid Based Complement Alternat Med 2012;2012:359282.
Nozaki K, Hikiami H, Goto H, Nakagawa T, Shibahara N, Shimada Y. Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis. Evid Based Complement Alternat Med 2006;3:359᾿64.
Huang SF, Hou RY, Gao SS, Ni XH, Du TF. Preliminary study on pattern of prescription compatibility of Chinese medicine for treatment of coronary heart disease. J Guangzhou Univ Tradit Chin Med (Chin) 2009;26:305᾿07.
Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol 2012;140:614᾿23.
0
Views
240
Downloads
5
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
